Every year, hundreds of thousands of discectomies relieve the pain and leave behind a hole in the disc wall that nothing closes. We are building what closes it.
Low back pain affected 619 million people globally in 2020 and is projected to reach 843 million by 2050. It is the single largest contributor to years lived with disability on Earth. In the United States alone, degenerative disc disease drives an estimated $90 billion in annual direct and indirect cost.
A large share of that burden begins as a mechanical failure. The annulus fibrosus — the tough, concentrically layered wall that contains the disc’s pressurized core — tears. The nucleus pushes through the breach and presses on the nerve root. The result is radiculopathy: leg pain, numbness, weakness, and for many patients the loss of the ability to work.
Lumbar disc herniation most commonly presents between the third and fifth decades of life, with a male-to-female ratio of roughly 2:1.
New lumbar disc herniations per 1,000 U.S. adults, every year
Annual incidence of sciatica in the general population
Lifetime prevalence of sciatica at the upper end of published estimates
Peak age range for symptomatic herniation — the working years
Axial and sagittal views: nucleus material breaches the annulus and contacts the traversing nerve root.
Unlike bone or skin, the annulus fibrosus is avascular and nearly acellular at its core. It has no meaningful capacity for self-repair. Once the wall is torn, the tear is permanent — and the disc continues to bear load through the defect for the rest of the patient’s life.
This is what turns a single acute event into a degenerative trajectory: reherniation, progressive height loss, and eventual fusion.
Lumbar discectomy is one of the most reliable operations in spine surgery for relieving acute radicular pain, and it is performed several hundred thousand times a year in the United States. But the procedure is fundamentally subtractive. The surgeon reaches the herniated material through the very defect the herniation created — and then leaves that defect open.
What remains is a disc with a permanent breach in its containment structure, under physiological load, with no biological capacity to close.
Published reherniation rates range from 1% to over 20%, with 5–10% widely accepted. At ten-year follow-up, recurrent disc herniation is the single most frequent reason for reoperation, at roughly 10%.
Patients left with an annular defect wider than 6 mm reherniate at approximately 27% — versus about 1% for small, competent defects. Surgeons can identify the high-risk patient intraoperatively. They simply cannot fix the anatomy.
Roughly $300,000 in revision surgery is spent for every 100 index lumbar discectomies. Across the U.S. health system this is conservatively estimated at $1.4 billion per year.
Recurrent herniation leads to repeat discectomy with measurably poorer outcomes, then to progressive degeneration, then to fusion. None of these steps restore normal disc function. Each one costs more than the last.
Discectomy and microdiscectomy are among the most commonly performed surgical procedures in the United States — roughly 300,000 to 400,000 cases annually, placing the procedure in the same national volume tier as hysterectomy and hernia repair. Typical episode cost exceeds $20,000.
Discectomy sits inside the ten most-performed surgical procedures in the United States — and is the only one on this list with no product addressing its principal failure mode.
300,000 procedures at a $5,000 average selling price
~600,000 discectomies performed worldwide each year
At a conservative 10% capture of the U.S. market
Compound annual growth in procedure volume
No biologic annulus repair product is FDA-cleared today. The barrier to entry is not competitive share — it is the absence of any viable option. The first credible entrant defines the category rather than fighting for a slice of it.
Baby boomers and Gen X are moving through the peak window for symptomatic disc degeneration. Procedure volume grows with the aging population, independent of any change in practice pattern.
Discectomy is shifting rapidly into ambulatory surgery centers, where facility economics strongly favor single-use, high-margin adjuncts that reduce revision risk. The site-of-service shift is a tailwind, not a threat.
A durable repair option creates a path to capture volume that today escalates into the 450,000-procedure fusion market — a far larger and more expensive pool of patients who never wanted a fusion in the first place.
Annular repair is not a subsegment play. Nearly every discectomy creates an annular defect, and nearly every annular defect is a candidate for closure. That makes the serviceable population coextensive with the procedure itself — a rare structural advantage in a mature surgical market.
Add a 96% gross margin at roughly $200 COGS, a delivery model that fits the existing surgical workflow, and international pathways that allow revenue generation ahead of U.S. approval, and the economics compound quickly.
Lumbar spine, posterior view. L4–L5 and L5–S1 account for the large majority of symptomatic herniations.
AnnuNovo exists to address one specific, well-defined, unsolved problem: the annular defect left behind after lumbar discectomy. Not a broader platform ambition. Not an incremental improvement to the discectomy itself. The hole in the wall.
We are not describing the technology on this page.
Our approach is not a plug, an anchor, or a mesh. It works with the body’s own repair machinery rather than against it.
It is designed to be delivered by the surgeon during the procedure already being performed — no new access, no new operation.
The underlying science has been under continuous preclinical development and peer review for more than ten years.
Detailed technical, preclinical, regulatory, and financial information is available to qualified investors, surgeons, and strategic partners under confidentiality.
AnnuNovo’s clinical direction is shaped by leading spine surgeons across academic medicine, high-volume private practice, and international centers of excellence.
Hospital for Special Surgery
Co-Chief, HSS Spine · Orthopedic Spine Surgeon
Barrow Neurological Institute
Chief, Spinal Disorders · Neurosurgeon
Rush University Medical Center
Orthopedic Spine Surgeon
Germany & Dubai
Neurosurgeon and Orthopedic Surgeon
Texas Back Institute
Endoscopic Spine Surgery
Weill Cornell Medicine
Neurosurgeon
Duke University
Neurosurgeon
We are raising a $3M–$5M seed to Series A round to fund supply chain, delivery system development, large animal studies, FDA pre-submission, and international commercial strategy.
If you perform discectomy and have opinions about what the procedure leaves behind, we want to hear them. Advisory and early clinical involvement opportunities are open.
Distribution, licensing, and partnership conversations welcome — particularly for international markets where we intend to commercialize first.
jblain@annunovo.com
Jason Blain, Chief Executive Officer